R. Holman, S. Paul, M. Bethel, D. Matthews, and H. Neil, 10-Year Follow-up of Intensive Glucose Control in Type 2 Diabetes, New England Journal of Medicine, vol.359, issue.15, pp.1577-1589, 2008.
DOI : 10.1056/NEJMoa0806470

S. Kahn, S. Haffner, and M. Heise, Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy, New England Journal of Medicine, vol.355, issue.23, pp.2477-2480, 2006.
DOI : 10.1056/NEJMoa066224

M. Nauck, E. Homberger, and E. Siegel, Incretin Effects of Increasing Glucose Loads in Man Calculated from Venous Insulin and C-Peptide Responses*, The Journal of Clinical Endocrinology & Metabolism, vol.63, issue.2, pp.492-498, 1986.
DOI : 10.1210/jcem-63-2-492

T. Vilsboll and J. Holst, Incretins, insulin secretion and Type 2 diabetes mellitus, Diabetologia, vol.47, issue.3, pp.357-366, 2004.
DOI : 10.1007/s00125-004-1342-6

R. Elliott, L. Morgan, J. Tredger, S. Deacon, J. Wright et al., Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man: acute post-prandial and 24-h secretion patterns, Journal of Endocrinology, vol.138, issue.1, pp.159-166, 1993.
DOI : 10.1677/joe.0.1380159

G. Bell, R. Sanchez-pescador, P. Laybourn, and R. Najarian, Exon duplication and divergence in the human preproglucagon gene, Nature, vol.143, issue.5924, pp.368-371, 1983.
DOI : 10.1038/304368a0

C. Orskov, J. Holst, S. Knuhtsen, F. Baldissera, S. Poulsen et al., Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*, Endocrinology, vol.119, issue.4, pp.1467-1475, 1986.
DOI : 10.1210/endo-119-4-1467

B. Kreymann, G. Williams, M. Ghatei, and S. Bloom, GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MAN, The Lancet, vol.330, issue.8571, pp.1300-1304, 1987.
DOI : 10.1016/S0140-6736(87)91194-9

D. Drucker, P. J. Mojsov, S. Chick, W. Habener, and J. , Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line., Proceedings of the National Academy of Sciences, vol.84, issue.10, pp.3434-3438, 1987.
DOI : 10.1073/pnas.84.10.3434

L. Baggio and D. Drucker, Biology of Incretins: GLP-1 and GIP, Gastroenterology, vol.132, issue.6, pp.2131-2157, 2007.
DOI : 10.1053/j.gastro.2007.03.054

G. Weir, S. Mojsov, G. Hendrick, and J. Habener, Glucagonlike Peptide I (7-37) Actions on Endocrine Pancreas, Diabetes, vol.38, issue.3, pp.338-342, 1989.
DOI : 10.2337/diab.38.3.338

L. Scrocchi, B. Marshall, S. Cook, P. Brubaker, and D. Drucker, Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling, Diabetes, vol.47, issue.4, pp.632-639, 1998.
DOI : 10.2337/diabetes.47.4.632

D. Song, L. Getty-kaushik, E. Tseng, J. Simon, B. Corkey et al., Glucose-Dependent Insulinotropic Polypeptide Enhances Adipocyte Development and Glucose Uptake in Part Through Akt Activation, Gastroenterology, vol.133, issue.6, pp.1796-1805, 2007.
DOI : 10.1053/j.gastro.2007.09.005

P. Mcclean, N. Irwin, R. Cassidy, J. Holst, V. Gault et al., GIP receptor antagonism reverses obesity, insulin resistance, and associated metabolic disturbances induced in mice by prolonged consumption of high-fat diet, AJP: Endocrinology and Metabolism, vol.293, issue.6, pp.1746-1755, 2007.
DOI : 10.1152/ajpendo.00460.2007

K. Miyawaki, Y. Yamada, and H. Yano, Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice, Proceedings of the National Academy of Sciences, vol.96, issue.26, pp.14843-14847, 1999.
DOI : 10.1073/pnas.96.26.14843

K. Miyawaki, Y. Yamada, and N. Ban, Inhibition of gastric inhibitory polypeptide signaling prevents obesity, Nature Medicine, vol.8, issue.7, pp.738-742, 2002.
DOI : 10.1038/nm727

T. Hansotia, L. Baggio, and D. Delmeire, Double Incretin Receptor Knockout (DIRKO) Mice Reveal an Essential Role for the Enteroinsular Axis in Transducing the Glucoregulatory Actions of DPP-IV Inhibitors, Diabetes, vol.53, issue.5, pp.1326-1335, 2004.
DOI : 10.2337/diabetes.53.5.1326

M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt, Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes, Diabetologia, vol.24, issue.Suppl 82, pp.46-52, 1986.
DOI : 10.1007/BF02427280

T. Vilsboll, T. Krarup, C. Deacon, S. Madsbad, and J. Holst, Reduced Postprandial Concentrations of Intact Biologically Active Glucagon-Like Peptide 1 in Type 2 Diabetic Patients, Diabetes, vol.50, issue.3, pp.609-613, 2001.
DOI : 10.2337/diabetes.50.3.609

J. Meier and M. Nauck, Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired ??-Cell Function?, Diabetes, vol.59, issue.5, pp.1117-1125, 2010.
DOI : 10.2337/db09-1899

M. Toft-nielsen, M. Damholt, and S. Madsbad, Determinants of the Impaired Secretion of Glucagon-Like Peptide-1 in Type 2 Diabetic Patients, The Journal of Clinical Endocrinology & Metabolism, vol.86, issue.8, pp.3717-3723, 2001.
DOI : 10.1210/jcem.86.8.7750

E. Rask, T. Olsson, and S. Soderberg, Impaired Incretin Response After a Mixed Meal Is Associated With Insulin Resistance in Nondiabetic Men, Diabetes Care, vol.24, issue.9, pp.1640-1645, 2001.
DOI : 10.2337/diacare.24.9.1640

K. Vollmer, J. Holst, and B. Baller, Predictors of Incretin Concentrations in Subjects With Normal, Impaired, and Diabetic Glucose Tolerance, Diabetes, vol.57, issue.3, pp.678-687, 2008.
DOI : 10.2337/db07-1124

L. Ranganath, J. Beety, L. Morgan, J. Wright, R. Howland et al., Attenuated GLP-1 secretion in obesity: cause or consequence?, Gut, vol.38, issue.6, pp.916-919, 1996.
DOI : 10.1136/gut.38.6.916

E. Muscelli, A. Mari, and A. Casolaro, Separate Impact of Obesity and Glucose Tolerance on the Incretin Effect in Normal Subjects and Type 2 Diabetic Patients, Diabetes, vol.57, issue.5, pp.1340-1348, 2008.
DOI : 10.2337/db07-1315

C. Deacon, M. Nauck, M. Toft-nielsen, L. Pridal, B. Willms et al., Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects, Diabetes, vol.44, issue.9, pp.1126-1131, 1995.
DOI : 10.2337/diab.44.9.1126

C. Deacon, M. Nauck, J. Meier, K. Hucking, and J. Holst, Degradation of Endogenous and Exogenous Gastric Inhibitory Polypeptide in Healthy and in Type 2 Diabetic Subjects as Revealed Using a New Assay for the Intact Peptide, Journal of Clinical Endocrinology & Metabolism, vol.85, issue.10, pp.3575-3581, 2000.
DOI : 10.1210/jc.85.10.3575

S. Conarello, Z. Li, and J. Ronan, Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance, Proceedings of the National Academy of Sciences, vol.100, issue.11, pp.6825-6830, 2003.
DOI : 10.1073/pnas.0631828100

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC164531

D. Marguet, L. Baggio, and T. Kobayashi, Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26, Proceedings of the National Academy of Sciences, vol.97, issue.12, pp.6874-6879, 2000.
DOI : 10.1073/pnas.120069197

J. Pospisilik, S. Stafford, and H. Demuth, Long-Term Treatment With the Dipeptidyl Peptidase IV Inhibitor P32/98 Causes Sustained Improvements in Glucose Tolerance, Insulin Sensitivity, Hyperinsulinemia, and ??-Cell Glucose Responsiveness in VDF (fa/fa) Zucker Rats, Diabetes, vol.51, issue.4, pp.943-950, 2002.
DOI : 10.2337/diabetes.51.4.943

J. Pospisilik, J. Martin, and T. Doty, Dipeptidyl Peptidase IV Inhibitor Treatment Stimulates ??-Cell Survival and Islet Neogenesis in Streptozotocin-Induced Diabetic Rats, Diabetes, vol.52, issue.3, pp.741-750, 2003.
DOI : 10.2337/diabetes.52.3.741

R. Pederson, H. White, D. Schlenzig, R. Pauly, C. Mcintosh et al., Improved Glucose Tolerance in Zucker Fatty Rats by Oral Administration of the Dipeptidyl Peptidase IV Inhibitor Isoleucine Thiazolidide, Diabetes, vol.47, issue.8, pp.1253-1258, 1998.
DOI : 10.2337/diab.47.8.1253

J. Pospisilik, S. Stafford, H. Demuth, C. Mcintosh, and R. Pederson, Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study mice with beta-cell-specific overexpression of human islet amyloid polypeptide, Diabetes Regul.Pept, vol.51, issue.143, pp.2677-268397, 2002.

K. Raun, V. Voss, P. Gotfredsen, C. Golozoubova, V. Rolin et al., Liraglutide, a Long-Acting Glucagon-Like Peptide-1 Analog, Reduces Body Weight and Food Intake in Obese Candy-Fed Rats, Whereas a Dipeptidyl Peptidase-IV Inhibitor, Vildagliptin, Does Not, Diabetes, vol.56, issue.1, pp.8-15, 2007.
DOI : 10.2337/db06-0565

S. Kim, C. Nian, D. Doudet, and C. Mcintosh, Inhibition of Dipeptidyl Peptidase IV With Sitagliptin (MK0431) Prolongs Islet Graft Survival in Streptozotocin-Induced Diabetic Mice, Diabetes, vol.57, issue.5, pp.1331-1339, 2008.
DOI : 10.2337/db07-1639

A. Maida, T. Hansotia, C. Longuet, Y. Seino, and D. Drucker, Differential Importance of Glucose-Dependent Insulinotropic Polypeptide vs Glucagon-Like Peptide 1 Receptor Signaling for Beta Cell Survival in Mice, Gastroenterology, vol.137, issue.6, pp.2146-2157, 2009.
DOI : 10.1053/j.gastro.2009.09.004

J. Mu, A. Petrov, and G. Eiermann, Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes, European Journal of Pharmacology, vol.623, issue.1-3, pp.148-154, 2009.
DOI : 10.1016/j.ejphar.2009.09.027

J. Mu, J. Woods, and Y. Zhou, Chronic Inhibition of Dipeptidyl Peptidase-4 With a Sitagliptin Analog Preserves Pancreatic ??-Cell Mass and Function in a Rodent Model of Type 2 Diabetes, Diabetes, vol.55, issue.6, pp.1695-1704, 2006.
DOI : 10.2337/db05-1602

H. Mest and R. Mentlein, Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes, Diabetologia, vol.53, issue.Suppl 2, pp.616-620, 2005.
DOI : 10.1007/s00125-005-1707-5

G. Flock, L. Baggio, C. Longuet, and D. Drucker, Incretin Receptors for Glucagon-Like Peptide 1 and Glucose-Dependent Insulinotropic Polypeptide Are Essential for the Sustained Metabolic Actions of Vildagliptin in Mice, Diabetes, vol.56, issue.12, pp.3006-3013, 2007.
DOI : 10.2337/db07-0697

G. Herman, C. Stevens, V. Dyck, and K. , Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clinical Pharmacology & Therapeutics, vol.78, issue.6, pp.675-688, 2005.
DOI : 10.1016/j.clpt.2005.09.002

A. Bergman, C. Stevens, and Y. Zhou, Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers, Clinical Therapeutics, vol.28, issue.1, pp.55-72, 2006.
DOI : 10.1016/j.clinthera.2006.01.015

G. Herman, A. Bergman, and F. Liu, Pharmacokinetics and Pharmacodynamic Effects of the Oral DPP-4 Inhibitor Sitagliptin in Middle-Aged Obese Subjects, The Journal of Clinical Pharmacology, vol.379, issue.Suppl 2, pp.876-886, 2006.
DOI : 10.1177/0091270006289850

E. Villhauer, J. Brinkman, and G. Naderi, )-pyrrolidine:?? A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties, Journal of Medicinal Chemistry, vol.46, issue.13, pp.2774-2789, 2003.
DOI : 10.1021/jm030091l

Y. He, D. Serra, and Y. Wang, Pharmacokinetics and Pharmacodynamics of Vildagliptin??in??Patients?? with Type??2??Diabetes??Mellitus, Clinical Pharmacokinetics, vol.283, issue.8, pp.577-588, 2007.
DOI : 10.2165/00003088-200746070-00003

Y. He, Y. Wang, and J. Bullock, Pharmacodynamics of Vildagliptin in Patients With Type 2 Diabetes During OGTT, The Journal of Clinical Pharmacology, vol.91, issue.suppl 1, pp.633-641, 2007.
DOI : 10.1177/0091270006299137

D. Augeri, J. Robl, and D. Betebenner, Discovery and Preclinical Profile of Saxagliptin (BMS-477118):?? A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes, Journal of Medicinal Chemistry, vol.48, issue.15, pp.5025-5037, 2005.
DOI : 10.1021/jm050261p

P. Covington, R. Christopher, and M. Davenport, Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes, Clinical Therapeutics, vol.30, issue.3, pp.499-512, 2008.
DOI : 10.1016/j.clinthera.2008.03.004

S. Huttner, E. Graefe-mody, B. Withopf, A. Ring, and K. Dugi, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Oral Doses of BI 1356, an Inhibitor of Dipeptidyl Peptidase 4, in Healthy Male Volunteers, The Journal of Clinical Pharmacology, vol.78, issue.6, pp.1171-1178, 2008.
DOI : 10.1177/0091270008323753

T. Heise, E. Graefe-mody, S. Huttner, A. Ring, D. Trommeshauser et al., Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients, Diabetes, Obesity and Metabolism, vol.61, issue.8, pp.786-794, 2009.
DOI : 10.1111/j.1463-1326.2009.01046.x

A. Bergman, J. Cote, and Y. B. , Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Diabetes Care, vol.30, issue.7, pp.1862-1864, 2007.
DOI : 10.2337/dc06-2545

S. Vincent, J. Reed, and A. Bergman, Metabolism And Excretion of the Dipeptidyl Peptidase 4 Inhibitor [14C]Sitagliptin in Humans, Drug Metabolism and Disposition, vol.35, issue.4, pp.533-538, 2007.
DOI : 10.1124/dmd.106.013136

J. Chan, R. Scott, A. Ferreira, and J. , Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency, Diabetes, Obesity and Metabolism, vol.10, issue.7, pp.545-555, 2008.
DOI : 10.1111/j.1463-1326.2006.00704.x

U. Graefe-mody, C. Friedrich, and A. Port, Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin*, Diabetes, Obesity and Metabolism, vol.13, issue.Suppl. 1, pp.939-946, 2011.
DOI : 10.1111/j.1463-1326.2011.01458.x

B. Ahren, Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin ??? diabetes control and potential adverse events, Best Practice & Research Clinical Endocrinology & Metabolism, vol.23, issue.4, pp.487-498, 2009.
DOI : 10.1016/j.beem.2009.03.003

G. Lankas, B. Leiting, and R. Roy, Dipeptidyl Peptidase IV Inhibition for the Treatment of Type 2 Diabetes: Potential Importance of Selectivity Over Dipeptidyl Peptidases 8 and 9, Diabetes, vol.54, issue.10, pp.2988-2994, 2005.
DOI : 10.2337/diabetes.54.10.2988

B. Burkey, P. Hoffmann, U. Hassiepen, J. Trappe, M. Juedes et al., Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited, Diabetes, Obesity and Metabolism, vol.54, issue.11, pp.1057-1061, 2008.
DOI : 10.1111/j.1463-1326.2008.00860.x

P. Aschner, M. Kipnes, J. Lunceford, M. Sanchez, C. Mickel et al., Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes, Diabetes Care, vol.29, issue.12, pp.2632-2637, 2006.
DOI : 10.2337/dc06-0703

B. Goldstein, M. Feinglos, J. Lunceford, J. Johnson, and D. Williams-herman, Effect of Initial Combination Therapy With Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, and Metformin on Glycemic Control in Patients With Type 2 Diabetes, Diabetes Care, vol.30, issue.8, pp.1979-1987, 2007.
DOI : 10.2337/dc07-0627

B. Charbonnel, A. Karasik, J. Liu, M. Wu, and G. Meininger, Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone, Diabetes Care, vol.29, issue.12, pp.2638-2643, 2006.
DOI : 10.2337/dc06-0706

J. Rosenstock, R. Brazg, P. Andryuk, K. Lu, and P. Stein, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Clinical Therapeutics, vol.28, issue.10, pp.1556-1568, 2006.
DOI : 10.1016/j.clinthera.2006.10.007

M. Nauck, G. Meininger, D. Sheng, L. Terranella, and P. Stein, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial, Diabetes, Obesity and Metabolism, vol.118, issue.2, pp.194-205, 2007.
DOI : 10.1016/j.clinthera.2006.10.007

T. Seck, M. Nauck, and D. Sheng, Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study, International Journal of Clinical Practice, vol.287, issue.5, pp.562-576, 2010.
DOI : 10.1111/j.1742-1241.2010.02353.x

R. Pratley, M. Nauck, and T. Bailey, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial, The Lancet, vol.375, issue.9724, pp.1447-1456, 2010.
DOI : 10.1016/S0140-6736(10)60307-8

F. Pi-sunyer, A. Schweizer, D. Mills, and S. Dejager, Efficacy and tolerability of vildagliptin monotherapy in drug-na??ve patients with type 2 diabetes, Diabetes Research and Clinical Practice, vol.76, issue.1, pp.132-138, 2007.
DOI : 10.1016/j.diabres.2006.12.009

E. Bosi, R. Camisasca, C. Collober, E. Rochotte, and A. Garber, Effects of Vildagliptin on Glucose Control Over 24 Weeks in Patients With Type 2 Diabetes Inadequately Controlled With Metformin, Diabetes Care, vol.30, issue.4, pp.890-895, 2007.
DOI : 10.2337/dc06-1732

E. Ferrannini, V. Fonseca, and B. Zinman, Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy, Diabetes, Obesity and Metabolism, vol.30, issue.2, pp.157-166, 2009.
DOI : 10.1111/j.1463-1326.2008.00994.x

D. Prato, S. Barnett, A. Huisman, H. Neubacher, D. Woerle et al., Effect of linagliptin monotherapy on glycaemic control and markers of ??-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes, Obesity and Metabolism, vol.55, issue.(Suppl. 1), pp.258-267, 2011.
DOI : 10.1111/j.1463-1326.2010.01350.x

M. Taskinen, J. Rosenstock, and I. Tamminen, Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes, Obesity and Metabolism, vol.63, issue.Suppl. 1, pp.65-74, 2011.
DOI : 10.1111/j.1463-1326.2010.01326.x

L. Sloan, J. Newman, C. Sauce, M. Von-eynatten, S. Patel et al., Safety and Efficacy of Linagliptin in Type 2 Diabetes Patients with Severe Renal Impairment, Diabetes, vol.60, p.114, 2011.

R. Defronzo, P. Fleck, C. Wilson, and Q. Mekki, Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study, Diabetes Care, vol.31, issue.12, pp.2315-2317, 2008.
DOI : 10.2337/dc08-1035

M. Nauck, G. Ellis, P. Fleck, C. Wilson, and Q. Mekki, Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study, International Journal of Clinical Practice, vol.39, issue.1, pp.46-55, 2009.
DOI : 10.1111/j.1742-1241.2008.01933.x

R. Pratley, M. Kipnes, P. Fleck, C. Wilson, and Q. Mekki, Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy, Diabetes, Obesity and Metabolism, vol.10, issue.Suppl. 1, pp.167-176, 2009.
DOI : 10.1111/j.1463-1326.2008.01016.x

J. Rosenstock, M. Rendell, J. Gross, P. Fleck, C. Wilson et al., without causing weight gain or increased hypoglycaemia, Diabetes, Obesity and Metabolism, vol.321, issue.12, pp.1145-1152, 2009.
DOI : 10.1111/j.1463-1326.2009.01124.x

J. Rosenstock, S. Sankoh, and J. List, Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes, Diabetes, Obesity and Metabolism, vol.445, issue.5, pp.376-386, 2008.
DOI : 10.1111/j.1463-1326.2005.00539.x

J. Rosenstock, C. Aguilar-salinas, E. Klein, S. Nepal, J. List et al., Effect of saxagliptin monotherapy in treatment-na??ve patients with type 2 diabetes, Current Medical Research and Opinion, vol.25, issue.10, pp.2401-2411, 2009.
DOI : 10.1185/03007990903178735

R. Defronzo, M. Hissa, and A. Garber, The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone, Diabetes Care, vol.32, issue.9, pp.1649-1655, 2009.
DOI : 10.2337/dc08-1984

P. Hollander, J. Li, E. Allen, and R. Chen, Saxagliptin Added to a Thiazolidinedione Improves Glycemic Control in Patients with Type 2 Diabetes and Inadequate Control on Thiazolidinedione Alone, The Journal of Clinical Endocrinology & Metabolism, vol.94, issue.12, pp.4810-4819, 2009.
DOI : 10.1210/jc.2009-0550

A. Chacra, G. Tan, A. Apanovitch, S. Ravichandran, J. List et al., Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, International Journal of Clinical Practice, vol.41, issue.Suppl. 1, pp.1395-1406, 2009.
DOI : 10.1111/j.1742-1241.2009.02143.x

M. Nowicki, I. Rychlik, and H. Haller, Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment, Diabetes, Obesity and Metabolism, vol.12, issue.3 Suppl. 3, pp.523-532, 2011.
DOI : 10.1111/j.1463-1326.2011.01382.x

A. Scheen, G. Charpentier, C. Ostgren, A. Hellqvist, and I. Gause-nilsson, Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus, Diabetes/Metabolism Research and Reviews, vol.11, issue.7, pp.540-549, 2010.
DOI : 10.1002/dmrr.1114

E. Yacoubi, M. Vaugeois, J. Marguet, and D. , Behavioral characterization of CD26 deficient mice in animal tests of anxiety and antidepressant-like activity, Behavioural Brain Research, vol.171, issue.2, pp.279-285, 2006.
DOI : 10.1016/j.bbr.2006.04.003

URL : https://hal.archives-ouvertes.fr/hal-00135369

S. Yan, D. Marguet, J. Dobers, W. Reutter, and H. Fan, Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen, European Journal of Immunology, vol.33, issue.6, pp.1519-1527, 2003.
DOI : 10.1002/eji.200323469

S. Kim, C. Nian, D. Doudet, and C. Mcintosh, Dipeptidyl Peptidase IV Inhibition With MK0431 Improves Islet Graft Survival in Diabetic NOD Mice Partially via T-Cell Modulation, Diabetes, vol.58, issue.3, pp.641-651, 2009.
DOI : 10.2337/db08-1101

N. Ta, Y. Li, C. Schuyler, M. Lopes-virella, and Y. Huang, DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes, Atherosclerosis, vol.213, issue.2, pp.429-435, 2010.
DOI : 10.1016/j.atherosclerosis.2010.08.064

K. Christopherson, G. Hangoc, C. Mantel, and H. Broxmeyer, Modulation of Hematopoietic Stem Cell Homing and Engraftment by CD26, Science, vol.305, issue.5686, pp.1000-1003, 2004.
DOI : 10.1126/science.1097071

M. Nauck, T. Vilsboll, B. Gallwitz, A. Garber, and S. Madsbad, Incretin-Based Therapies: Viewpoints on the way to consensus, Diabetes Care, vol.32, issue.suppl_2, pp.223-231, 2009.
DOI : 10.2337/dc09-S315

L. Nikolaidis, S. Mankad, and G. Sokos, Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful Reperfusion, Circulation, vol.109, issue.8, pp.962-965, 2004.
DOI : 10.1161/01.CIR.0000120505.91348.58

M. Arakawa, T. Mita, and K. Azuma, Inhibition of Monocyte Adhesion to Endothelial Cells and Attenuation of Atherosclerotic Lesion by a Glucagon-like Peptide-1 Receptor Agonist, Exendin-4, Diabetes, vol.59, issue.4, pp.1030-1037, 2010.
DOI : 10.2337/db09-1694

R. Gros, X. You, and L. Baggio, Cardiac Function in Mice Lacking the Glucagon-Like Peptide-1 Receptor, Endocrinology, vol.144, issue.6, pp.2242-2252, 2003.
DOI : 10.1210/en.2003-0007

G. Sokos, L. Nikolaidis, S. Mankad, D. Elahi, and R. Shannon, Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart Failure, Journal of Cardiac Failure, vol.12, issue.9, pp.694-699, 2006.
DOI : 10.1016/j.cardfail.2006.08.211

G. Sokos, H. Bolukoglu, and J. German, Effect of Glucagon-Like Peptide-1 (GLP-1) on Glycemic Control and Left Ventricular Function in Patients Undergoing Coronary Artery Bypass Grafting, The American Journal of Cardiology, vol.100, issue.5, pp.824-829, 2007.
DOI : 10.1016/j.amjcard.2007.05.022

J. Best, B. Hoogwerf, and W. Herman, Risk of Cardiovascular Disease Events in Patients With Type 2 Diabetes Prescribed the Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Exenatide Twice Daily or Other Glucose-Lowering Therapies: A retrospective analysis of the LifeLink database, Diabetes Care, vol.34, issue.1, pp.90-95, 2011.
DOI : 10.2337/dc10-1393

M. Halbirk, H. Norrelund, and N. Moller, Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure, AJP: Heart and Circulatory Physiology, vol.298, issue.3, pp.1096-1102, 2010.
DOI : 10.1152/ajpheart.00930.2009

P. Read, F. Khan, P. Heck, S. Hoole, and D. Dutka, DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease, Circulation: Cardiovascular Imaging, vol.3, issue.2, pp.195-201, 2010.
DOI : 10.1161/CIRCIMAGING.109.899377

M. Sauve, K. Ban, and M. Momen, Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice, Diabetes, vol.59, issue.4, pp.1063-1073, 2010.
DOI : 10.2337/db09-0955

R. Frederich, J. Alexander, and F. Fiedorek, A Systematic Assessment of Cardiovascular Outcomes in the Saxagliptin Drug Development Program for Type 2 Diabetes, Postgraduate Medicine, vol.361, issue.7, pp.16-27, 2010.
DOI : 10.1113/jphysiol.2009.176461

M. Monami, I. Iacomelli, N. Marchionni, and E. Mannucci, Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials, Nutrition, Metabolism and Cardiovascular Diseases, vol.20, issue.4, pp.224-235, 2010.
DOI : 10.1016/j.numecd.2009.03.015

M. Bethel, J. Green, R. Califf, and R. Holman, Rationale and Design of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) ADA, 2009.

J. Rosenstock, N. Marx, and S. Kahn, Rationale and Design of the CAROLINA Trial: An Active Comparator CARdiOvascular Outcome

W. White, G. Bakris, and R. Bergenstal, EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE), American Heart Journal, vol.162, issue.4, pp.620-626, 2011.
DOI : 10.1016/j.ahj.2011.08.004